# AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes

> **NCT07697391** · PHASE4 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Anhui Medical University** · enrollment: 285 (estimated)

## Conditions studied

- Obesity
- Diabetes Mellitus, Type 2

## Interventions

- **BEHAVIORAL:** AI-Assisted Intensive Lifestyle Intervention
- **DRUG:** Tirzepatide
- **BEHAVIORAL:** Standard Lifestyle Management

## Key facts

- **NCT ID:** NCT07697391
- **Lead sponsor:** The First Affiliated Hospital of Anhui Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-20
- **Primary completion:** 2027-10-31
- **Final completion:** 2028-01-31
- **Target enrollment:** 285 (ESTIMATED)
- **Last updated:** 2026-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07697391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07697391, "AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07697391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*